A meta-analysis of atosiban supplementation among patients undergoing assisted reproduction
- 373 Downloads
Evidence for the efficacy of atosiban in improving pregnancy outcomes among patients undergoing assisted reproductive technology (ART) remains inconsistent.
The PubMed, EMBASE, and CNKI databases were searched using keywords such as ‘atosiban’, ‘infertility’, and ‘ART’. Studies that explored the efficacy of atosiban in the field of ART for patients with embryo transfer (ET) were included if they evaluated pregnancy outcomes. Combing using subgroups and sensitivity analysis were conducted, and risk ratios (RRs), and 95% confidence intervals (CIs) were calculated.
Six studies were included. Atosiban treatment could improve pregnancy outcomes for all patients undergoing ET, especially for the subgroups of patients with repeated implantation failure (RIF) (implantation rate: RR = 1.806, 95% CI = 1.473–2.215; clinical pregnancy rate: RR = 1.725, 95% CI = 1.394–2.135; live birth rate: RR = 2.141, 95% CI = 1.494–3.068), as shown by the comparison with placebo or no-treatment groups. However, no statistical significance was detected in subgroups of patients undergoing their first or second ET cycle. In addition, no significant differences were observed in positive pregnancy tests, miscarriage rates, multiple pregnancy rates, or ectopic pregnancy rates.
Supplementation with atosiban has a positive effect on ART and embryo transfer procedure, especially for women undergoing their third or more ET cycle.
KeywordsAtosiban Infertility Assisted reproductive technology
Author contribution statement
JL, YC, and HYZ conceived and designed the study. JL, ARW, and YC analyzed the data. HYZ and JL wrote the “Introduction” and “Discussion”. JL, ARW, and YC wrote the “Materials and methods” and “Results”. HYZ, ARW, and YC provided significant advice for the manuscript. JL, HYZ, and ARW were mainly responsible to write and modify the draft.
Compliance with ethical standards
There is no funding.
Conflict of interest
Authors (J.L., Y.C., AR. W., and HY. Z.) declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.HFEA fertility treatment in 2010: trends and figures. http://www.hfea.gov.uk/6771.html. Accessed 11 Dec 2011
- 2.Canadian ART Register (CARTR) latest annual figures. http://www.cfas.ca/index.php?option=com_content&view=article&id=1129%. Accessed 11 Dec 2011
- 3.Ferraretti AP, Goossens V, Kupka M, Bhattacharya S, de Mouzon J, Castilla JA, Erb K, Korsak V, Nyboe Andersen A, European IVF-Monitoring (EIM) Consortium for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe (2013) Assisted reproductive technology in Europe, 2009: results generated from European registers by ESHRE. Hum Reprod 28:2318–2331CrossRefPubMedGoogle Scholar
- 5.Pierzynski P, Reinheimer TM, Kuczynski W (2007) Oxytocin antagonists may improve infertility treatment. Fertil Steril 88(213):e19–e22Google Scholar
- 15.He Y, Wu H, He X, Xing Q, Zhou P, Cao Y, Wei Z (2016) Application of atosiban in frozen-thawed cycle patients with different times of embryo transfers. Gynecol Endocrinol 5:1–5Google Scholar
- 21.Zhang Y, Chu Y, Luo H, Zhang Y, Xue F (2014) Ifluence of atosiban on pregnancy outcomes in patients with repeated implantation failure in freezing embryo transfer cycle. Chin J Fam Plann 22(5):325–328Google Scholar
- 22.Chen C, Liu L, Li Y, Gao Y, Geng Y (2014) Oxytocin receptor antagonist atosiban in blastocyst thaw transplantation in clinical observation. Reprod Contracept 34(8):633–637Google Scholar
- 33.Vedernikov Y, Betancourt A, Shi S, Shi L, Reinheimer T, Garfield R (2006) Oxytocin antagonistic effect of barusiban and atosiban in isolated uterine artery from late pregnant rats. In: Presentation at the Annual Scientific Meeting of the Society for Gynecologic Investigation, 2006. Toronto, CanadaGoogle Scholar